Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Transmedics Group Inc shares valued at $632,250 were sold by Basile Edward M on May 27 ’25. At $126.45 per share, Basile Edward M sold 5,000 shares. The insider’s holdings dropped to 2,866 shares worth approximately $0.37 million following the completion of this transaction.
Also, EDWARD BASILE purchased 5,000 shares, netting a total of over 632,250 in proceeds.
Before that, Weill David had sold 732 shares from its account. In a trade valued at $90,680, the Director traded Transmedics Group Inc shares for $123.88 each. Upon closing the transaction, the insider’s holdings decreased to 732 shares, worth approximately $1.55 million.
As published in a research note from JP Morgan on December 17, 2024, Transmedics Group Inc [TMDX] has been rated down from an Overweight to a Neutral and the price target has been revised to $75 from $116. Analysts at Needham downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in late November. As of October 29, 2024, Oppenheimer has reiterated its “an Outperform” rating for TMDX. Earlier on October 29, 2024, Needham resumed its rating. Their recommendation was “a Buy” for TMDX stock.
Analyzing TMDX Stock Performance
During the last five days, there has been a surge of approximately 5.26%. Over the course of the year, Transmedics Group Inc shares have jumped approximately 104.80%. Shares of the company reached a 52-week high of $130.48 on 05/29/25 and a 52-week low of $55.00 on 01/21/25.
Support And Resistance Levels for Transmedics Group Inc (TMDX)
According to the 24-hour chart, there is a support level at 126.11, which, if violated, would cause prices to drop to 124.52. In the upper region, resistance lies at 129.88. The next price resistance is at 132.06. RSI (Relative Strength Index) is 77.94 on the 14-day chart, showing overbought technical sentiment.
